Literature DB >> 22943122

Current progress in pharmacologic treatment strategies for alcohol dependence.

Peter Clapp1.   

Abstract

Alcoholism is a progressive neurological disorder that represents one of the leading preventable causes of morbidity and mortality in the USA. Individuals with alcohol dependence may exhibit differences in their sensitivity to intoxication, the age at which they begin heavy drinking or the presentation of comorbid psychiatric illness. The heterogeneous nature of the disorder has complicated efforts to predict treatment outcomes, indicating a need for improved diagnostic and therapeutic approaches. Pharmaceutical development has focused on treating the symptoms of alcohol withdrawal, reducing consumption of and craving for alcohol, preventing relapse and treating associated psychiatric problems. Current therapies may be optimized by combining psychosocial and pharmacologic approaches to treat alcoholic patients with the most appropriate regimen to achieve the desired therapeutic outcome. This article will describe the neurobiological mechanisms of dependence on alcohol in brief and review major medications approved for the treatment of alcoholism with regard to recent clinical evidence for the therapeutic efficacy of each agent. Investigations on the use of drugs with other indications (e.g., antidepressants and anticonvulsants) to target alcohol-dependent subtypes will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943122     DOI: 10.1586/ecp.12.31

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  8 in total

1.  Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking.

Authors:  Jennifer A Rinker; Diana B Fulmer; Heather Trantham-Davidson; Maren L Smith; Robert W Williams; Marcelo F Lopez; Patrick K Randall; L Judson Chandler; Michael F Miles; Howard C Becker; Patrick J Mulholland
Journal:  Alcohol       Date:  2016-06-27       Impact factor: 2.405

2.  Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption.

Authors:  Natalie S McGuier; William C Griffin; Justin T Gass; Audrey E Padula; Elissa J Chesler; Patrick J Mulholland
Journal:  Addict Biol       Date:  2015-06-23       Impact factor: 4.280

3.  Operant ethanol self-administration increases extracellular-signal regulated protein kinase (ERK) phosphorylation in reward-related brain regions: selective regulation of positive reinforcement in the prefrontal cortex of C57BL/6J mice.

Authors:  Sara Faccidomo; Michael C Salling; Christina Galunas; Clyde W Hodge
Journal:  Psychopharmacology (Berl)       Date:  2015-06-28       Impact factor: 4.530

4.  Novel anticonvulsants for reducing alcohol consumption: A review of evidence from preclinical rodent drinking models.

Authors:  A E Padula; N S McGuier; W C Griffin; M F Lopez; H C Becker; P J Mulholland
Journal:  OA Alcohol       Date:  2013-02-01

5.  Effects of nitric oxide synthase inhibition in the dorsolateral periaqueductal gray matter on ethanol withdrawal-induced anxiety-like behavior in rats.

Authors:  Vivian Taciany Bonassoli; Ewandro Braz Contardi; Humberto Milani; Rúbia Maria Weffort de Oliveira
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

Review 6.  Targeting Neuronal Networks with Combined Drug and Stimulation Paradigms Guided by Neuroimaging to Treat Brain Disorders.

Authors:  Carl L Faingold; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2015-07-06       Impact factor: 7.519

7.  Pharmacotherapy for Alcohol Use Disorders: Physicians' Perceptions and Practices.

Authors:  Caridad Ponce Martinez; Priyanka Vakkalanka; Nassima Ait-Daoud
Journal:  Front Psychiatry       Date:  2016-11-14       Impact factor: 4.157

8.  Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.

Authors:  David J Hinton; Marely Santiago Vázquez; Jennifer R Geske; Mario J Hitschfeld; Ada M C Ho; Victor M Karpyak; Joanna M Biernacka; Doo-Sup Choi
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.